Filament Health and Jaguar Health's Joint Venture Completes Successful Import of Coca Leaf for Psychedelic Research

Author: Benzinga Newsdesk | September 21, 2023 07:33am

 Filament Health Corp. (OTCQB:FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or "Filament Health"), a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences ("Magdalena"), a joint venture formed by Filament and Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar Health"), successfully completed an import of coca leaf to Filament's Metro Vancouver research and development facility. The import of coca leaf was authorized by the Peruvian Health Authority, Dirección General de Medicamentos Insumos y Drogas (DIGEMID), and acquired from the Empresa Nacional de la Coca (ENACO), which is the only company in Peru authorized to collect, distribute and export coca leaf and their derived products. The imported leaves were received by Psilo Scientific, a wholly-owned subsidiary of Filament Health, and will be used for initial research purposes to look at neuropsychiatric indications.

Posted In: FLHLF JAGX